| Clinical Trial Name | Clinical Trial Full Title | Principal Investigator | Project site status | Clinical trials gov number |
|---|---|---|---|---|
| AGS-16C3F-15-3 | A Multi-center, Open Label, Randomized Phase 2 Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell Carcinoma | Hotte, Dr Sebastien | Open | NCT02639182 |
| FRACTION-RCC | A Phase 2, Fast Real-time Assessment of Combination Therapies in Immuno-ONcology Study in Participants with Advanced Renal Cell Carcinoma | Hotte, Dr Sebastien | Open | NCT02996110 |
| MK-3475-426 | A Phase III Randomized, Open-label, Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Axitinib versus Sunitinib Monotherapy as a First-line Treatment for Locally Advanced or Metastatic Renal Cell Carcinoma (mRCC) (KEYNOTE-426) | Hotte, Dr Sebastien | Open | NCT02853331 |
| CO39303 | A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER TRIAL TESTING IPATASERTIB PLUS ABIRATERONE PLUS PREDNISONE/PREDNISOLONE, RELATIVE TO PLACEBO PLUS ABIRATERONE PLUS PREDNISONE/PREDNISOLONE IN PATIENTS WITH ASYMPTOMATIC OR MILDLY SYMPTOMATIC METASTATIC CASTRATE-RESISTANT PROSTATE CANCER WITH PTEN-LOSS (PTEN DIAGNOSTIC POSITIVE) TUMORS | Mukherjee, Dr Som | Open | NCT03072238 |
| PROfound | A Phase III, Open Label, Randomized Study to Assess the Efficacy and Safety of Olaparib (Lynparza™) Versus Enzalutamide or Abiraterone Acetate in Men with Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment with a New Hormonal Agent and Have Homologous Recombination Repair Gene Mutations (PROfound) | Hotte, Dr Sebastien | Open | NCT02987543 |
| WO39210 | A PHASE III, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF ATEZOLIZUMAB (ANTI-PD-L1 ANTIBODY) AS ADJUVANT THERAPY IN PATIENTS WITH PD-L1-SELECTED RENAL CELL CARCINOMA AT INTERMEDIATE TO HIGH RISK OF DEVELOPING METASTASIS FOLLOWING NEPHRECTOMY | Hotte, Dr Sebastien | Open | NCT03024996 |
| IND.223 | A Phase II Study of Palbociclib, A CDK4/6 Inhibitor, in Patients with Metastatic Castration-Resistant Prostate Cancer | Mukherjee, Dr Som | Open | NCT02905318 |
| OCOG-2013-PETMUSE | Impact of Positron Emission Tomography (PET) Imaging in Muscle-invasive Urothelial Carcinoma of the Bladder Staging | Mukherjee, Dr Som | Open | NCT02462239 |
| OCOG-2016-MISTER | Assessment of New Molecular Imaging Strategies for Prostate Cancer: Predictive Value of Established and Novel PET Radiotracers in Castration-Resistant Prostate Cancer | Hotte, Dr Sebastien | Open | NCT02813226 |
| OZM-053 | A Phase II, Multi-Centre Study, of Stereotactic Radiotherapy for Oligo-Progression in Renal Cell Cancer Patients Receiving 1st Line Sunitinib Therapy | Swaminath, Dr Anand | Open | NCT02019576 |
| OZM-054 | A Phase II, randomized, multi-center study of cabazitaxel versus abiraterone or enzalutamide in poor prognosis-metastatic castration-resistant prostate cancer | Hotte, Dr Sebastien | Open | NCT02254785 |
| PACE | PACE - International Randomized Study of Laparoscopic Prostatectomy vs Robotic Radiosurgery and Conventionally Fractionated Radiotherapy vs Radiosurgery for Early Stage Organ-Confined Prostate Cancer | Dayes, Dr Ian | Open | NCT01584258 |
| TOPCOP | TOward Personalizing Care for Older men with mCRPC - understanding and predicting treatment toxicities (the TOPCOP study) | Hotte, Dr Sebastien | Open | NCT02512185 |
| TRITON2 | A Multicenter, Open-label Phase 2 Study of Rucaparib in Patients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency | Hotte, Dr Sebastien | Open | NCT02952534 |
| WO30070 | A PHASE III, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, PARTIAL -BLIND STUDY OF ATEZOLIZUMAB (ANTI-PDL1 ANTIBODY) MONOTHERAPY AND IN COMBINATION WITH PLATIMUN BASED THERAPY VERSUS PLATINUM BASED THERAPY PLUS PLACEBO IN PATIENTS WITH UNTREATED LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA | Mukherjee, Dr Som | Open | NCT02807636 |
| IND.232 | A Phase II Study of Durvalumab With or Without Tremelimumab in Patients With Metastatic castration Resistant Prostate Cancer | Hotte, Dr Sebastien | On hold | NCT02788773 |
| Prostate HBI | Non-Targeted Low Dose Radiotherapy For Recurrent Prostate Cancer | Dayes, Dr Ian | On hold | NCT03196778 |
Find a Trial
Contact Us